Stock listing
NASDAQ:CVRX CVRx, Inc. Stock
Home listing (NASDAQ) of CVRx, Inc.
Follow CVRx, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CVRX
$0.501 USD -0.103 (-17.1%)
Close on Nov 20, 2026
- Day range
- $0.497 – $0.569 USDNov 20, 2026
- Volume
- 519,859 sharesNov 20, 2026
- Market cap
- $14.27M USDAt the close on Nov 20, 2026 · price × 28.49M shares outstanding
- 52-week range
- $0.497 – $10.280 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.39M USDMedian day 519,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CVRX · Home | $0.501 USD | -0.103 (-17.1%) | 519,859 | $0.529 | $0.569 | $0.497 | $0.604 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CVRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.501 | -0.103 | -17.1% | $0.529 | $0.569 | $0.497 | 519,859 | |
| $0.604 | -0.007 | -1.1% | $0.611 | $0.672 | $0.604 | 198,157 | |
| $0.611 | -0.002 | -0.3% | $0.640 | $0.675 | $0.571 | 637,315 | |
| $0.613 | +0.006 | +0.9% | $0.620 | $0.620 | $0.566 | 513,863 | |
| $0.607 | -0.023 | -3.6% | $0.630 | $0.662 | $0.604 | 715,780 | |
| $0.630 | -0.070 | -10.0% | $0.698 | $0.701 | $0.630 | 591,282 | |
| $0.700 | +0.005 | +0.7% | $0.723 | $0.740 | $0.700 | 369,289 | |
| $0.695 | -0.085 | -10.9% | $0.800 | $0.822 | $0.674 | 1,109,074 | |
| $0.781 | -0.088 | -10.2% | $0.949 | $0.966 | $0.720 | 3,447,204 | |
| $0.869 | -0.601 | -40.9% | $1.250 | $1.250 | $0.774 | 5,392,300 | |
| $1.470 | -0.110 | -7.0% | $1.540 | $1.555 | $1.405 | 299,300 | |
| $1.580 | +0.200 | +14.5% | $1.400 | $1.600 | $1.400 | 368,200 | |
| $1.380 | +0.010 | +0.7% | $1.380 | $1.450 | $1.335 | 305,300 | |
| $1.370 | -0.040 | -2.8% | $1.410 | $1.450 | $1.340 | 294,100 | |
| $1.410 | -0.015 | -1.1% | $1.410 | $1.460 | $1.380 | 272,700 | |
| $1.425 | +0.025 | +1.8% | $1.420 | $1.455 | $1.360 | 256,100 | |
| $1.400 | -0.015 | -1.1% | $1.430 | $1.451 | $1.280 | 822,300 | |
| $1.415 | -0.035 | -2.4% | $1.440 | $1.490 | $1.350 | 447,300 | |
| $1.450 | +0.030 | +2.1% | $1.410 | $1.470 | $1.350 | 224,000 | |
| $1.420 | +0.050 | +3.6% | $1.370 | $1.470 | $1.300 | 199,900 | |
| $1.370 | 0.000 | 0.0% | $1.370 | $1.420 | $1.360 | 247,500 | |
| $1.370 | -0.020 | -1.4% | $1.380 | $1.380 | $1.300 | 282,000 | |
| $1.390 | +0.040 | +3.0% | $1.360 | $1.435 | $1.360 | 295,900 | |
| $1.350 | +0.050 | +3.8% | $1.300 | $1.360 | $1.275 | 358,000 | |
| $1.300 | -0.090 | -6.5% | $1.390 | $1.390 | $1.255 | 382,700 | |
| $1.390 | +0.050 | +3.7% | $1.360 | $1.440 | $1.332 | 360,700 | |
| $1.340 | -0.020 | -1.5% | $1.330 | $1.400 | $1.280 | 893,200 | |
| $1.360 | -0.120 | -8.1% | $1.490 | $1.490 | $1.350 | 489,800 | |
| $1.480 | -0.100 | -6.3% | $1.580 | $1.665 | $1.465 | 470,100 | |
| $1.580 | -0.100 | -6.0% | $1.660 | $1.680 | $1.560 | 398,700 | |
| $1.680 | +0.010 | +0.6% | $1.640 | $1.680 | $1.550 | 519,200 | |
| $1.670 | +0.050 | +3.1% | $1.620 | $1.760 | $1.620 | 896,600 | |
| $1.620 | +0.060 | +3.8% | $1.540 | $1.690 | $1.540 | 537,100 | |
| $1.560 | +0.010 | +0.6% | $1.570 | $1.620 | $1.505 | 576,600 | |
| $1.550 | +0.020 | +1.3% | $1.580 | $1.665 | $1.510 | 1,059,600 | |
| $1.530 | -0.220 | -12.6% | $1.745 | $1.790 | $1.500 | 1,463,800 | |
| $1.750 | -0.880 | -33.5% | $2.630 | $2.650 | $1.650 | 4,274,900 | |
| $2.630 | +0.040 | +1.5% | $2.600 | $2.755 | $2.530 | 373,400 | |
| $2.590 | -0.110 | -4.1% | $2.690 | $2.790 | $2.530 | 382,000 | |
| $2.700 | +0.170 | +6.7% | $2.560 | $2.700 | $2.510 | 461,600 | |
| $2.530 | -0.190 | -7.0% | $2.730 | $2.730 | $2.510 | 693,700 | |
| $2.720 | -0.170 | -5.9% | $2.890 | $2.890 | $2.700 | 481,700 | |
| $2.890 | -0.080 | -2.7% | $2.950 | $3.070 | $2.860 | 666,200 | |
| $2.970 | -0.070 | -2.3% | $3.030 | $3.060 | $2.910 | 289,100 | |
| $3.040 | +0.040 | +1.3% | $2.990 | $3.065 | $2.920 | 810,500 | |
| $3.000 | -0.020 | -0.7% | $3.040 | $3.100 | $2.975 | 301,200 | |
| $3.020 | +0.020 | +0.7% | $2.990 | $3.130 | $2.920 | 415,900 | |
| $3.000 | 0.000 | 0.0% | $2.990 | $3.080 | $2.850 | 494,900 | |
| $3.000 | +0.120 | +4.2% | $2.860 | $3.000 | $2.790 | 548,400 | |
| $2.880 | +0.020 | +0.7% | $2.860 | $2.901 | $2.750 | 1,001,400 | |
| $2.860 | +0.030 | +1.1% | $2.830 | $2.860 | $2.700 | 372,900 | |
| $2.830 | -0.100 | -3.4% | $2.900 | $2.950 | $2.760 | 555,200 | |
| $2.930 | -0.120 | -3.9% | $3.030 | $3.050 | $2.810 | 619,600 | |
| $3.050 | +0.040 | +1.3% | $2.990 | $3.110 | $2.960 | 856,000 | |
| $3.010 | -0.060 | -2.0% | $3.110 | $3.175 | $2.980 | 613,900 | |
| $3.070 | +0.030 | +1.0% | $3.060 | $3.160 | $2.962 | 530,000 | |
| $3.040 | +0.080 | +2.7% | $2.930 | $3.060 | $2.895 | 780,700 | |
| $2.960 | +0.010 | +0.3% | $2.970 | $2.990 | $2.810 | 737,800 | |
| $2.950 | -0.090 | -3.0% | $3.030 | $3.150 | $2.940 | 496,700 | |
| $3.040 | -0.230 | -7.0% | $3.250 | $3.290 | $3.020 | 447,500 | |
| $3.270 | -0.100 | -3.0% | $3.310 | $3.400 | $3.150 | 884,400 | |
| $3.370 | +0.220 | +7.0% | $3.170 | $3.420 | $3.130 | 1,123,956 | |
| $3.150 | +0.310 | +10.9% | $2.990 | $3.290 | $2.860 | 1,620,454 | |
| $2.840 | 0.000 | 0.0% | $2.860 | $2.960 | $2.820 | 742,100 | |
| $2.840 | +0.020 | +0.7% | $2.810 | $2.951 | $2.770 | 746,500 |
- Ticker
- NASDAQ:CVRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
CVRx to Participate at the Piper Sandler 38th Annual Healthcare Conference
Latest earnings call · Nov 5, 2026
CVRx (NASDAQ:CVRX) Q3 2026 Earnings Call
Replay and transcript
Latest news
CVRx to Participate at the Piper Sandler 38th Annual Healthcare Conference
Nov 17, 2026
Closed $0.604 (-1.1%) on Nov 18, 2026
CVRx Reports Third Quarter 2026 Financial and Operating Results
Nov 5, 2026
Closed $0.869 (-40.9%) on Nov 6, 2026
CVRx to Participate in Upcoming Investor Conferences
Nov 2, 2026
Closed $1.38 (+0.7%) on Nov 3, 2026
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
Oct 22, 2026
Closed $1.42 (+3.6%) on Oct 23, 2026
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
Sep 29, 2026
Closed $1.75 (-33.5%) on Sep 30, 2026
CVRx Appoints John Landry as Chief Financial Officer
Sep 21, 2026
Closed $2.89 (-2.7%) on Sep 22, 2026
CVRx Responds to Letter from Pointillist Family Office
Aug 25, 2026
Closed $3.37 (+7.0%) on Aug 25, 2026
Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
Aug 24, 2026
Closed $3.15 (+10.9%) on Aug 24, 2026
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
Aug 24, 2026
Closed $3.15 (+10.9%) on Aug 24, 2026
CVRx Announces Sales Leadership Transition
Aug 11, 2026
Closed $2.60 (+9.7%) on Aug 11, 2026
CVRx, Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 30 in the last 12 months · 115 in all · newest Nov 17, 2026 · oldest 2021
- Calls
- 22 calls with a replay · 22 with a transcript · latest Nov 5, 2026
- Decks
- 16 decks · latest Jun 8, 2023
Where CVRx, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CVRX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CVRX | BOATS | United States | USD |
Valuation
EV/sales 0.2× against a median of 0.8×: 2nd lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $14.18M USD
- P/E
- Loss
- EV/sales
- 0.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.0×
- Gross margin
- 86.9%
- Operating margin
- −81.9%
- Net margin
- −88.3%
- Debt to equity
- 4.2×
- Beta vs S&P 500
- 1.28
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CVRx, Inc. · NASDAQ:CVRX | US$14.27M | US$14.18M | n/a | 0.2× | n/a | 1.0× | −88.3% | 4.2× | 1.28 |
| SG Healthcare Co., Ltd. · KRX:398120 | US$15.78M | US$11.93M | 19.3× | 0.6× | n/a | 0.9× | 4.2% | 0.0× | n/a |
| Careplus Group Bhd. · MYX:CAREPLS | US$15.50M | US$20.64M | n/a | 0.8× | n/a | 0.3× | −11.1% | 0.1× | n/a |
| HeartBeam, Inc. · NASDAQ:BEAT | US$15.50M | US$9.44M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.93 |
| Lifecare ASA · OSL:LIFE | US$15.21M | US$11.43M | n/a | 175× | n/a | 2.7× | n/a | 0.0× | n/a |
| Control Bionics Ltd. · ASX:CBL | US$15.13M | US$14.16M | n/a | 4.5× | n/a | 3.6× | −152.4% | 0.1× | n/a |
| Micro-X Ltd. · ASX:MX1 | US$14.45M | US$16.66M | n/a | 1.7× | n/a | 4.5× | −65.5% | 1.3× | n/a |
| Perimeter Medical Imaging AI Inc · TSXV:PINK | US$14.45M | US$8.00M | n/a | 3.8× | n/a | 3.5× | −478.7% | 0.0× | 1.55 |
| Suzhou Basecare Medical Corp. Ltd. Class H · HKEX:2170 | US$13.52M | US$8.12M | n/a | 0.2× | n/a | 0.1× | −66.8% | 0.4× | n/a |
| CytoSorbents Corporation · NASDAQ:CTSO | US$13.12M | US$26.43M | n/a | 0.7× | n/a | n/a | −46.7% | n/a | 1.42 |
| SANUWAVE Health, Inc. · NASDAQ:SNWV | US$12.90M | US$24.87M | 3.1× | 0.6× | 34.8× | 4.5× | 10.1% | 6.5× | 0.88 |
| Median of the others | US$14.79M | US$13.05M | 11.2× | 0.8× | 34.8× | 2.7× | −56.1% | 0.1× | 1.49 |
Forecasts
1 strong buy · 5 hold · 1 sell · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.65 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.07 · 7 analysts
- Revenue, year to Dec 2026
- 56.4M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Kevin Hykes | President and CEO |
| Martha Shadan | President and Chief Executive Officer |
| Michael Dale | Chief Executive Officer and President |
| John Landry | Chief Financial Officer |
| Joseph Slattery | Executive Vice President and Chief Financial Officer |
| Brent Binkowski | Chief Operating Officer |
| Greg Morrison | Chief Human Resources Officer |
| Philip B. Adamson | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Kirk Nielsen | Director |
| Mitch Hill | Director |
| Mudit K. Jain | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| CVRx (NASDAQ:CVRX) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 4:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q1 2026 Earnings Call | Mon, May 11, 2026 · 4:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q4 2025 Earnings Call | Thu, Feb 12, 2026 · 4:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q2 2025 Earnings Call | Mon, Aug 04, 2025 · 4:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q1 2025 Earnings Call | Thu, May 08, 2025 · 4:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q4 2024 Earnings Call | Tue, Feb 04, 2025 · 4:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q3 2024 Earnings Call | Tue, Oct 29, 2024 · 4:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q2 2024 Earnings Call | Mon, Jul 29, 2024 · 4:30 PM ET | Replay |
All 22 calls
| Call | When | Status |
|---|---|---|
| CVRx (NASDAQ:CVRX) Q1 2024 Earnings Call | Tue, Apr 30, 2024 · 5:00 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q4 2023 Earnings Call | Thu, Jan 25, 2024 · 8:00 AM ET | Replay |
| CVRx (NASDAQ:CVRX) Q3 2023 Earnings Call | Thu, Oct 26, 2023 · 5:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q2 2023 Earnings Call | Tue, Jul 25, 2023 · 5:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q1 2023 Earnings Call | Thu, Apr 27, 2023 · 5:00 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q4 2022 Earnings Call | Thu, Jan 26, 2023 · 5:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q3 2022 Earnings Call | Tue, Nov 01, 2022 · 5:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q2 2022 Earnings Call | Thu, Jul 28, 2022 · 5:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q1 2022 Earnings Call | Mon, Apr 25, 2022 · 4:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q4 2021 Earnings Call | Tue, Feb 15, 2022 · 5:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q3 2021 Earnings Call | Thu, Nov 04, 2021 · 5:30 PM ET | Replay |
| CVRx (NASDAQ:CVRX) Q2 2021 Earnings Call | Wed, Aug 04, 2021 · 5:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −40.9% |
| Q2 2026 | Aug 6, 2026 · After close | −59.8% |
| Q1 2026 | May 11, 2026 · After close | −23.8% |
| Q4 2025 | Feb 12, 2026 · After close | −13.0% |
| Q3 2025 | Nov 5, 2025 · After close | +2.7% |
| Q2 2025 | Aug 4, 2025 · After close | −9.9% |
| Q1 2025 | May 8, 2025 · After close | −38.7% |
| Q4 2024 | Feb 4, 2025 · After close | −7.2% |
| Q3 2024 | Oct 29, 2024 · After close | +31.0% |
| Q2 2024 | Jul 29, 2024 · After close | −14.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 30, 2024 · After close | −34.8% |
| Q4 2023 | Jan 25, 2024 · After close | −6.8% |
| Q3 2023 | Oct 26, 2023 · After close | +2.4% |
| Q2 2023 | Jul 25, 2023 · After close | +5.4% |
| Q1 2023 | Apr 27, 2023 · After close | +22.8% |
| Q4 2022 | Jan 26, 2023 · After close | +2.9% |
| Q3 2022 | Nov 1, 2022 · After close | +1.1% |
| Q2 2022 | Jul 28, 2022 · After close | +16.9% |
| Q1 2022 | Apr 25, 2022 · After close | +11.4% |
| Q4 2021 | Feb 15, 2022 · After close | −6.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 43rd Annual William Blair Growth Stock Conference, June 2023 | Conference | 22 slides | Jun 8, 2023 |
| Technical Presentation (March 2023) | Technical | 36 slides | Mar 21, 2023 |
| Technical Presentation (February 2022) | Technical | 8 slides | February 2022 |
| Technical Presentation (May 2013) | Technical | 16 slides | May 2013 |
| Technical Presentation (May 2013) | Technical | 24 slides | May 2013 |
| Technical Presentation (May 2013) | Technical | 19 slides | May 2013 |
| Technical Presentation (May 2013) | Technical | 11 slides | May 2013 |
| Technical Presentation (May 2013) | Technical | 9 slides | May 2013 |
| Technical Presentation (August 2012) | Technical | 19 slides | Aug 30, 2012 |
| American College of Cardiology, 61st Annual Scientific Sessions (March 2012) | Conference | 16 slides | Mar 25, 2012 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (2011) | Technical | 19 slides | Oct 5, 2011 |
| Technical Presentation (2011) | Technical | 21 slides | Oct 5, 2011 |
| Technical Presentation (October 2011) | Technical | 23 slides | October 2011 |
| Technical Presentation (August 2011) | Technical | 11 slides | Aug 30, 2011 |
| Technical Presentation (October 2009) | Technical | 13 slides | Oct 3, 2009 |
| Technical Presentation (April 2009) | Technical | 15 slides | Apr 8, 2009 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Tranche closed: US$9.5M in the latest tranche | Apr 7, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Jun 29, 2021.
- Price
- US$18.00 a share
- Shares offered
- 7,000,000 shares of common stock
- Offering size
- US$126 million
- Underwriters' option
- Up to 1,050,000 more shares
- Listing
- CVRX on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Piper Sandler, William Blair, Canaccord Genuity · In the order on the cover
- Shares delivered
- On or about Jul 2, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 9, 2021 |
| Filed publicly | Jun 4, 2021 |
| Amended once | Jun 23, 2021 |
| Shares registered with an exchange | Jun 25, 2021 |
| Declared effective by the SEC | Jun 29, 2021 |
| Final prospectus, with the price | Jul 1, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 1, 2021 |
| EFFECT · Notice that a registration is effective | Jun 29, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jun 29, 2021 |
| CERT · Exchange's certificate of listing | Jun 28, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 25, 2021 |
| CORRESP · Letter to the SEC | Jun 25, 2021 |
| CORRESP · Letter to the SEC | Jun 25, 2021 |
| S-1/A · Registration statement, amended | Jun 23, 2021 |
| CORRESP · Letter to the SEC | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 4, 2021 |
All 17 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Jun 4, 2021 |
| UPLOAD · Letter from the SEC | May 27, 2021 |
| DRSLTR · Letter to the SEC with a draft | May 14, 2021 |
| DRS/A · Draft registration statement, amended | May 14, 2021 |
| UPLOAD · Letter from the SEC | May 7, 2021 |
| DRSLTR · Letter to the SEC with a draft | Apr 9, 2021 |
| DRS · Draft registration statement | Apr 9, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 1, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 56.7M | 51.3M | 39.3M | 22.5M | 13.0M | 6.05M | 6.26M |
| Cost of revenue | 8.31M | 8.33M | 6.26M | 5.00M | 3.64M | 1.44M | 1.68M |
| Gross profit | 48.3M | 43.0M | 33.0M | 17.5M | 9.40M | 4.61M | 4.57M |
| Research and development | 11.1M | 11.1M | 11.6M | 9.95M | 7.50M | 6.41M | 8.66M |
| Selling, general and administrative | 88.5M | 91.3M | 64.5M | 50.0M | 27.9M | 9.72M | 6.11M |
| Operating income | -51.3M | -59.5M | -43.1M | -42.5M | -26.0M | -11.5M | -10.2M |
| Depreciation and amortization | 756.0K | 619.0K | 522.0K | 412.0K | 168.0K | 75.0K | 56.0K |
| EBITDA | -50.5M | -58.9M | -42.6M | -42.1M | -25.8M | -11.4M | -10.1M |
| Interest expense | 5.83M | 4.40M | 1.80M | 165.0K | 2.22M | 2.47M | 1.72M |
| Income before tax | -53.3M | -59.9M | -41.1M | -41.3M | -43.0M | -14.0M | -14.6M |
| Income tax | -18.0K | 55.0K | 147.0K | 109.0K | 91.0K | 85.0K | 73.0K |
| Net income | -53.3M | -60.0M | -41.2M | -41.4M | -43.1M | -14.1M | -14.6M |
| Earnings per share, basic | -2.04 | -2.65 | -1.99 | -2.02 | -4.16 | -37.01 | -30.32 |
| Earnings per share, diluted | -2.04 | -2.65 | -1.99 | -2.02 | -4.16 | -37.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 75.7M | 105.9M | 90.6M | 106.2M | 142.1M | 59.1M | 25.7M |
| Receivables | 10.7M | 9.27M | 7.60M | 5.50M | 2.56M | 1.28M | 719.0K |
| Inventory | 12.2M | 12.1M | 11.0M | 6.96M | 3.88M | 3.34M | 2.07M |
| Current assets | 101.6M | 129.8M | 112.1M | 122.9M | 151.1M | 64.3M | 28.9M |
| Property, plant and equipment | 2.24M | 2.50M | 1.76M | 1.70M | 1.43M | 410.0K | 174.0K |
| Total assets | 104.8M | 133.4M | 115.2M | 124.9M | 152.5M | 64.8M | 29.1M |
| Accounts payable | 3.83M | 2.58M | 1.88M | 1.72M | 510.0K | 483.0K | 437.0K |
| Current liabilities | 13.3M | 10.8M | 7.86M | 8.09M | 5.91M | 7.98M | 8.61M |
| Long-term debt | 49.5M | 49.3M | 29.2M | 6.75M | 0 | 19.3M | 19.0M |
| Total debt | 49.5M | 49.3M | 29.2M | 6.75M | 0 | 19.3M | 19.0M |
| Total liabilities | 65.5M | 62.4M | 39.3M | 15.8M | 6.59M | 28.0M | 308.1M |
| Shareholders' equity | 39.3M | 71.1M | 75.9M | 109.2M | 146.0M | -293.2M | -279.0M |
| Shares outstanding | 26.3M | 25.3M | 20.9M | 20.7M | 20.4M | 360.4K | 482.6K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -40.2M | -39.1M | -39.0M | -42.7M | -27.7M | -16.1M | -12.8M |
| Capital spending | -580.0K | -1.36M | -591.0K | -685.0K | -1.18M | -311.0K | -106.0K |
| Free cash flow | -40.8M | -40.5M | -39.6M | -43.4M | -28.9M | -16.4M | -12.9M |
| Cash from investing | -580.0K | -1.36M | -591.0K | -685.0K | -1.18M | -311.0K | -106.0K |
| Cash from financing | 10.5M | 55.9M | 24.0M | 7.49M | 111.9M | 49.8M | 29.5M |
| Share buybacks | 771.0K | -1.00K | 0 | ||||
| Change in cash | -30.2M | 15.4M | -15.6M | -35.9M | 83.0M | 33.4M | 16.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 12, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 5, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 21, 2026 | Management or board change | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 24, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 8-K · Current report | Jun 9, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2026 | Meeting outcome | SEC |
| SD · Specialized disclosure | May 28, 2026 | ESG report | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 13, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 13, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 13, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 12, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4/A · Change in ownership, amended | Jan 8, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 16, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| DEL AM | Nov 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| S-3 · Registration statement | Nov 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2025 | Meeting outcome | SEC |
| SD · Specialized disclosure | May 23, 2025 | ESG report | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 7, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 20, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Feb 18, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 18, 2025 | Annual report | SEC |
| 3 · Initial statement of ownership | Feb 14, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 4, 2025 | Results | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 5, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 4, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 1, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2024 | Results | SEC |
| 8-K · Current report | Oct 1, 2024 | Financing | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 2, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2024 | Results | SEC |
| 144 · Notice of proposed sale | Jul 26, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 25, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 24, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 23, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 22, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 16, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 1, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 7, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 7, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 7, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 7, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2024 | Current report | SEC |
| SD · Specialized disclosure | May 16, 2024 | ESG report | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 11, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 14, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 9, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 9, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 9, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Feb 2, 2024 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Feb 2, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 2, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 31, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 25, 2024 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 19, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jan 2, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 29, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Dec 26, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2023 | Financing | SEC |
| 10-Q · Quarterly report | Oct 31, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 26, 2023 | Results | SEC |
| 4 · Change in ownership | Oct 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 10, 2023 | Other filings | SEC |
| 4 · Change in ownership | Aug 7, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 3, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 2, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 25, 2023 | Results | SEC |
| 8-K · Current report | Jun 8, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2023 | Insider trade | SEC |
| SD · Specialized disclosure | May 26, 2023 | ESG report | SEC |
| 4 · Change in ownership | May 18, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Apr 27, 2023 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2023 | Meeting notice | SEC |
| 8-K · Current report | Mar 21, 2023 | Current report | SEC |
| 8-K · Current report | Mar 15, 2023 | Financing | SEC |
| 8-K · Current report | Feb 21, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Feb 10, 2023 | Offer document | SEC |
| 10-K · Annual report | Feb 10, 2023 | Annual report | SEC |
This page holds 200 of 350 filings. Open Filings
Cap table
Built by 6ix from CVRx, Inc.’s releases · as of Oct 29, 2026
- Common shares
- 28,485,019
- Fully diluted
- 28,485,019
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 28,485,019 | Oct 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 29, 2026 | 28,485,019 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ali Behbahani Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Black Diamond Therapeutics, Inc. (Director · Since at least Jan 29, 2020); Adaptimmune Therapeutics PLC (Director · Since at least Jul 2, 2019); CRISPR Therapeutics AG (Director · Since at least Jun 11, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past) | Director · Jun 29, 2021 – Jun 4, 2024 · Past |
| Joseph Slattery Other companies: ImageneBio, Inc. (Director · Since at least Nov 1, 2025); Replimune Group, Inc. (Director · Since at least Jul 19, 2018); Omega Alpha SPAC (Director · Jan 6, 2021 – Jan 6, 2021 · Past); Morphic Holding Inc (Director · Jun 26, 2019 – Aug 16, 2024 · Past); Asensus Surgical Inc (EVP and CFO · Oct 2, 2013 – May 13, 2019 · Past); Baxano Surgical Inc (Executive V.P. and CFO · Nov 29, 2007 – May 31, 2013 · Past); Digene Corp (Chief Financial Officer & SVP · Jan 27, 2006 – Nov 20, 2006 · Past) | Executive Vice President and Chief Financial Officer · Since at least Jun 29, 2021 |
| Geoffrey B Pardo Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Shoulder Innovations, Inc. (Director · Since at least Jul 30, 2025); Inari Medical Inc (Director · May 21, 2020 – May 27, 2020 · Past); Vapotherm Inc (Director · Nov 13, 2018 – Jul 24, 2019 · Past) | Director · Jun 29, 2021 – Jul 2, 2021 · Past |
| Kevin J Ballinger Other companies: Shockwave Medical Inc (Director · May 16, 2023 – May 31, 2024 · Past); Silk Road Medical Inc (Director · Dec 3, 2020 – Sep 17, 2024 · Past); Boston Scientific Corporation (EVP & Pres, Interven Cardio · Jan 1, 2013 – Mar 3, 2020 · Past) | Director · Since at least Sep 3, 2024 |
| Mitch C Hill Other companies: Inari Medical Inc (Chief Financial Officer · May 21, 2020 – Oct 1, 2024 · Past); Ominto Inc (Director · Aug 10, 2015 – Jun 20, 2017 · Past) | Director · Since at least Sep 3, 2024 |
| Gregory Morrison Other companies: Wright Medical Group N.V (SVP, Human Resources · Jun 2, 2016 – Nov 10, 2017 · Past) | CHIEF HUMAN RESOURCES OFFICER · Since at least Mar 2, 2026 |
| John Landry Other companies: Vapotherm Inc (SVP & Chief Financial Officer · Nov 13, 2018 – Sep 20, 2024 · Past) | Chief Financial Officer · Since at least Sep 21, 2026 |
| John M Nehra Other companies: DaVita Inc. (Director · Mar 31, 2013 – May 15, 2024 · Past) | Director · Jun 29, 2021 – Jun 7, 2022 · Past |
| Kirk Nielsen Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026) | Director · Since at least May 12, 2025 |
| Martha Shadan Other companies: LeMaitre Vascular, Inc. (Director · Since at least May 29, 2025) | President and Chief Executive Officer · Since at least Jun 3, 2025 |
All 25 people
| Person | Seat |
|---|---|
| Michael Dale Other companies: Axogen, Inc. (President, Chief Executive Officer and Board Director · Since at least Oct 28, 2026) | Chief Executive Officer and President · Since at least Apr 20, 2026 |
| Brent Binkowski | Chief Operating Officer · Since at least Aug 4, 2025 |
| Craig E Palmer | SVP, U.S. SALES · Aug 2, 2022 – Mar 25, 2024 · Past |
| Dean Bruhn-Ding | VP OF REG. AFFAIRS AND QA · Jun 29, 2021 – Aug 2, 2022 · Past |
| Greg Morrison | Chief Human Resources Officer · Since at least Nov 4, 2026 |
| Jared Oasheim | CHIEF FINANCIAL OFFICER · Since at least Jun 29, 2021 |
| John Brintnall | CHIEF STRATEGY OFFICER AND SEC · Jun 29, 2021 – Apr 22, 2022 · Past |
| Kevin Hykes | President and CEO · Since at least Feb 12, 2024 |
| Liz Galle | VP OF GLOBAL CLINICAL RESEARCH · Jun 29, 2021 – Oct 16, 2023 · Past |
| Mitch Hill | Director · Since at least Jun 3, 2026 |
| Mudit K. Jain | Director · Since at least Jun 29, 2021 |
| Paul Verrastro | CHIEF MKTG & STRAT OFFICER · Since at least Jun 29, 2021 |
| Philip B Adamson | Chief Medical Officer · Since at least Feb 4, 2025 |
| Philip B. Adamson | Chief Medical Officer · Since at least Jan 22, 2026 |
| Robert Allen John | Chief Revenue Officer · Since at least Jun 27, 2024 |
Log in to ask 6ix AI your own questions about CVRx, Inc.